This article explores the global public health emergency of Monkeypox (Mpox), declared by the WHO. It addresses the virus’s transmission, clinical features, and challenges for healthcare systems, while highlighting strategies like surveillance, vaccination, and international cooperation to mitigate its impact and strengthen preparedness for future public health crises.
Monkeypox (Mpox) has rapidly emerged as a pressing public health concern worldwide, especially after the World Health Organization (WHO) declared it a Public Health Emergency of International Concern (PHEIC). This declaration emphasizes the urgent need for countries to coordinate efforts in containing the spread of Mpox and preventing its escalation into a more severe global crisis. The outbreak of Mpox in non-endemic regions in 2022 signified a disturbing shift in the spread of this once-isolated zoonotic disease, thrusting the global healthcare community into action.
This article examines the spread, clinical manifestations, public health challenges, and containment strategies surrounding Mpox. It also focuses on the roles healthcare professionals, governments, and international agencies play in curbing this public health emergency.
Mpox is a viral zoonotic disease caused by the Monkeypox virus, a member of the Orthopoxvirus genus. Initially identified in monkeys in 1958, the first human case was recorded in 1970 in the Democratic Republic of Congo (DRC). Historically, Mpox remained confined to Central and West African regions, where it spread from animals to humans primarily through contact with infected animals.
However, the 2022 outbreak saw a significant shift in the virus’s epidemiology, with Mpox spreading to non-endemic countries such as the United States, the United Kingdom, and various parts of Europe, Asia, and the Middle East. This new pattern of international transmission prompted global concern, eventually leading to the WHO’s global emergency declaration.
Monkeypox is primarily transmitted from animals to humans through direct contact with blood, bodily fluids, or the skin or mucosal lesions of infected animals, including rodents and primates. The virus can also be transmitted from human to human through respiratory droplets during close contact, direct contact with body fluids or Mpox lesions, and indirectly via contaminated materials like bedding or clothing.
The current outbreak has highlighted the challenges of controlling Mpox in non-endemic regions where public awareness and healthcare preparedness were low. Unlike diseases that spread rapidly via aerosols, Mpox’s transmission is slower due to its reliance on direct contact. Nevertheless, international travel, global interconnectedness, and close-knit communities have facilitated its global spread. With an incubation period of 6 to 13 days (and up to 21 days), Mpox has an extended window for transmission, further complicating containment efforts.
The clinical features of Mpox closely resemble those of smallpox, though Mpox is generally less severe. Early symptoms include fever, intense headache, back pain, muscle aches, and exhaustion. Within 1 to 3 days after the onset of fever, a rash develops, typically beginning on the face before spreading to other parts of the body. This rash progresses through macular, papular, vesicular, and pustular stages, eventually forming scabs that fall off.
One distinguishing feature of Mpox is lymphadenopathy (swollen lymph nodes), which helps differentiate it from smallpox. The rash is often more concentrated on the face and extremities, including the palms and soles, but can also affect the oral mucous membranes, genitals, and conjunctivae. In some cases, complications such as secondary bacterial infections, pneumonia, sepsis, encephalitis, and corneal infection leading to vision loss may occur.
Given the similar presentation of Mpox with other viral illnesses such as chickenpox, healthcare professionals must remain vigilant in identifying Mpox cases, particularly in regions where it is non-endemic. Polymerase Chain Reaction (PCR) testing of skin lesions remains the most reliable diagnostic tool for Mpox. Due to the difficulty of differentiating Mpox from other pox-like diseases based solely on symptoms, laboratory confirmation is essential.
Surveillance is crucial in containing Mpox outbreaks, and countries must adopt robust monitoring systems to detect and track cases. In response to the outbreak, international airports have implemented screening measures to identify individuals who may be infected with Mpox. These measures include temperature checks, visual examinations for rashes, and health questionnaires to identify potential exposures. Quarantine protocols have also been established in some regions to prevent the virus from spreading through international travel.
The re-emergence of Mpox as a public health threat presents several challenges for healthcare systems worldwide. Controlling the virus in regions unfamiliar with Mpox demands an extraordinary level of coordination, communication, and resource allocation.
Countries that had never experienced Mpox before 2022 have found themselves underprepared, both in terms of public awareness and healthcare infrastructure. The sudden increase in Mpox cases has stretched healthcare facilities, with many struggling to provide adequate isolation facilities, diagnostic tests, and treatments. Countries already overwhelmed by the Covid-19 pandemic have faced additional strain, especially in low-resource settings where health services are limited.
The smallpox vaccine, which provides cross-protection against Mpox, has been an effective tool in managing outbreaks. However, vaccine availability remains limited, especially in non-endemic regions. Governments and healthcare organisations have been tasked with balancing the need for vaccination among healthcare workers, at-risk individuals, and those in close contact with confirmed cases. The urgency of providing vaccines is particularly high in areas with significant outbreaks, but logistical hurdles—such as storage, distribution, and financing—continue to hinder effective vaccination campaigns.
Public health officials have also had to combat misinformation about Mpox, which has led to panic and stigma in some communities. Social media platforms have contributed to the spread of false information, which can undermine public health efforts. Additionally, the association of Mpox with certain populations or regions has created stigma, further complicating containment efforts. Addressing this requires clear, accurate communication and engagement with affected communities to promote understanding and cooperation.
To address the challenges posed by the Mpox outbreak, public health systems must adopt comprehensive and multi-faceted containment strategies that involve both preventive and curative measures.
Surveillance remains the first line of defense against Mpox outbreaks. Countries must enhance their surveillance systems to promptly detect new cases, particularly in non-endemic regions. This includes reinforcing border controls at international airports through health screening and quarantine measures for individuals arriving from high-risk areas. Identifying cases early enables public health authorities to isolate patients and prevent further spread.
Public education campaigns are critical in combating Mpox. Healthcare professionals must communicate clearly about how the virus spreads, its symptoms, and what steps individuals can take to protect themselves. Raising awareness about the importance of hygiene, reducing contact with infected individuals, and reporting symptoms early will help curb the spread of the virus. Public health campaigns should also work to dispel myths and reduce the stigma associated with Mpox.
The availability of smallpox vaccines has been crucial in responding to the Mpox outbreak. Countries must prioritise vaccination campaigns for healthcare workers, close contacts of confirmed cases, and high-risk groups, such as immunocompromised individuals. However, vaccine shortages remain a concern. Collaborative efforts between governments, global health organisations, and pharmaceutical companies are necessary to ensure the equitable distribution of vaccines worldwide.
In addition to vaccination, quarantine and isolation protocols are key to preventing the spread of Mpox, particularly at points of entry such as airports. Several countries have introduced mandatory quarantine measures for travellers from regions with high Mpox prevalence. Isolating symptomatic individuals and close contacts, along with tracking their movements, can prevent new outbreaks. Healthcare facilities must be equipped to safely isolate Mpox patients, protecting both healthcare workers and the broader public.
The global outbreak of Mpox has underscored the need for sustained investment in public health infrastructure and pandemic preparedness. The lessons learned from Covid-19 are now being applied to this new crisis, but the weaknesses exposed during that pandemic—such as inadequate healthcare capacity, fragmented public health systems, and inequitable access to vaccines—remain challenges in responding to Mpox.
Mpox highlights the need for resilient health systems that can quickly respond to emerging diseases. This includes increasing diagnostic capabilities, ensuring access to vaccines, and enhancing the supply of personal protective equipment (PPE). Strengthening health systems will not only help control Mpox but also prepare countries for future public health emergencies.
While the smallpox vaccine has been effective in managing Mpox, there is a need for more research into vaccines specifically designed for Mpox. Investing in vaccine research and development will not only help control this outbreak but will also contribute to global efforts to combat zoonotic diseases, which are expected to increase due to environmental changes and human activity.
The Mpox outbreak has reaffirmed the importance of global cooperation in managing public health crises. No country can combat an outbreak of this magnitude alone. International collaboration is essential for sharing data, resources, and strategies for containment. The WHO and other global health bodies must continue to play a central role in coordinating these efforts.
The resurgence of Monkeypox as a global health emergency has placed immense pressure on public health systems worldwide. The lessons learned from the Covid-19 pandemic, combined with coordinated global efforts, will be essential in managing this outbreak. By prioritising surveillance, public education, vaccination, and international cooperation, healthcare professionals and policymakers can mitigate the impact of Monkeypox and prevent it from becoming a more severe global crisis.
The outbreak of Mpox serves as a reminder that public health threats can emerge at any time, and preparedness is the best defense. Strengthening healthcare systems, ensuring equitable access to vaccines, and fostering international collaboration are vital to responding to such emergencies.
Mpox may not have the same transmission speed or mortality rate as other viruses like Covid-19, but its global spread has highlighted vulnerabilities in public health systems that require urgent attention. With the right strategies in place, including robust surveillance, timely quarantine measures at international airports, and effective community engagement, it is possible to contain the current outbreak and reduce the likelihood of future public health emergencies.
The world must remain vigilant, continuously adapting to new health threats. Investments in research, development of Mpox-specific vaccines, and improved global health equity will be crucial in ensuring that future generations are better equipped to face such challenges. As healthcare professionals, policymakers, and the international community join forces, there is hope that this crisis will be effectively managed, paving the way for stronger, and more resilient public health systems in the future.
Key Takeaways:
The global community must work together to mitigate the impact of Mpox and strengthen preparedness for future health crises.
-(1)-(1)-(1).jpg)
Dr. Venugopal Reddy is a Medical Director and Consultant Pediatrician at Ovum Hospitals. His career in pediatric medicine is marked by an exceptional educational foundation, beginning with an MBBS from Kurnool Medical College. His passion for pediatrics led him to further specialization with a DCH from Sydney University of Paediatrics, Australia, and an MD from Manipal Hospital. He holds prestigious MRCPCH and FRCPCH qualifications from the UK’s Royal College of Paediatrics and Child Health, and an FRACP from the Royal Australian College of Physicians, Australia. Additionally, Dr. Reddy has advanced studies in Pediatric Nutrition from Boston and Columbia Universities and an MBA in Hospital Management. Recently, he has completed a PhD in hospital management and its showcasing his commitment to pediatric healthcare excellence.
